Literature DB >> 28813644

Rotavirus disease course among immunocompromised patients; 5-year observations from a tertiary care medical centre.

P Bruijning-Verhagen1, M D Nipshagen2, H de Graaf3, M J M Bonten4.   

Abstract

Rotavirus (RV) is highly endemic inside and outside hospital-settings. Immunocompromised children and adults are at risk of complicated rotavirus gastroenteritis (RVGE), but general rotavirus disease severity in this group remains poorly described and rotavirus testing is not routinely performed beyond infancy. We assessed rotavirus disease among immunocompromised hospitalized patients.
METHODS: Rotavirus infections at a Dutch tertiary-care centre were identified from 5-year laboratory records. Rotavirus disease course was evaluated by chart review for each immunocompromised patient. In a matched case-control analysis, we assessed whether being immunocompromised predisposed to RVGE. Rotavirus testing practice for suspected infectious gastroenteritis in our hospital was determined over a 3-years period.
RESULTS: Out of 4584 RV tests performed, 294 were positive among hospitalized patients. Immunocompromised patients represented 57% (N = 20) of adult, and 12% (N = 32) of paediatric RVGE. A complicated disease course occurred in 81% of them and 33% required adaptations in underlying disease management. Immunocompromised adults were 7.4 times more likely todevelop RVGE compared to non-immunocompromised matched hospital-controls. Rotavirus testing in adult patients with suspected infectious gastroenteritis was uncommon (12% tested).
CONCLUSIONS: In our hospital, most adults with RVGE are immunocompromised compared to a much smaller proportion in children. RVGE in immunocompromised patients is associated with significant morbidity. Routine rotavirus testing beyond infancy should be recommended for immunocompromised patients with suspected infectious gastroenteritis.
Copyright © 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Complications; Hospital; Immunocompromised; Infectious gastroenteritis; Nosocomial; Rotavirus; Vaccination

Mesh:

Year:  2017        PMID: 28813644     DOI: 10.1016/j.jinf.2017.08.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  Cynomolgus Monkeys (Macaca fascicularis) as an Experimental Infection Model for Human Group A Rotavirus.

Authors:  Gentil Arthur Bentes; Juliana Rodrigues Guimarães; Eduardo de Mello Volotão; Alexandre Madi Fialho; Cleber Hooper; Ana Carolina Ganime; Noemi Rovaris Gardinali; Natália Maria Lanzarini; Alexandre Dos Santos da Silva; Jacob Pitcovski; José Paulo Leite; Marcelo Alves Pinto
Journal:  Viruses       Date:  2018-07-04       Impact factor: 5.048

2.  Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013-2018).

Authors:  Javier Arístegui; Santiago Alfayate-Miguelez; Begoña Carazo-Gallego; Elisa Garrote; Laura Díaz-Munilla; Mikel Mendizabal; María Méndez-Hernández; Elia Doménech; Belén Ferrer-Lorente; María Unsaín-Mancisidor; José Tomás Ramos-Amador; Marta Illán-Ramos; Borja Croche-Santander; Fernando Centeno Malfaz; Julián Rodríguez-Suárez; Manuel Cotarelo Suárez; María San-Martín; Jesús Ruiz-Contreras
Journal:  Hum Vaccin Immunother       Date:  2022-04-18       Impact factor: 4.526

3.  Development of a rapid homogeneous immunoassay for detection of rotavirus in stool samples.

Authors:  Ye Wang; Yuling Zheng; Yan Li; Shengwei Zhang; Xin Wang; Huijun Zong; Wenhua Huang; Decong Kong; Yongqiang Jiang; Peng Liu; Qingyu Lv; Hua Jiang
Journal:  Front Public Health       Date:  2022-08-04

4.  Diagnostic Accuracy of Four Commercial Triplex Immunochromatographic Tests for Rapid Detection of Rotavirus, Adenovirus, and Norovirus in Human Stool Samples.

Authors:  Jérôme Kaplon; Lucie Théry; Maxime Bidalot; Nadège Grangier; Jean Frappier; Ludwig Serge Aho Glélé; Alexis de Rougemont; Katia Ambert-Balay
Journal:  J Clin Microbiol       Date:  2020-12-17       Impact factor: 11.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.